Most workers remember a 60-day clock ticking the moment they leave a job with an unpaid 401(k) loan, but the rule many people actually face works nothing like that warning, and the difference could save tens of thousands of dollars in taxes and penalties.
IWM dominates small-cap portfolios by sheer habit, but a rival ETF with stricter admission standards has quietly beaten it across every major time horizon while charging a fraction of the fee.
Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.
eBay just delivered its strongest fundamentals in years, yet the stock slipped and Wall Street shrugged. One outlier analyst sees something the rest of the Street is missing, and the gap in price targets tells a story worth understanding.
Most people assume a hospital deductible is finished once they pay it, but Medicare Part A runs on a clock that can reset multiple times in a single year, and the bill that follows can catch even careful planners off guard.
Las Vegas keeps showing up on retirement shortlists for all the obvious reasons, but the math only works under two structural conditions most retirees overlook entirely before they sign the papers.
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
Josh paid off a decade of credit card debt, earns six figures with his wife, and somehow feels broke every week. Dave Ramsey heard one word repeated three times and immediately knew exactly what was destroying their finances and their marriage.
I encourage everyone to [read this](https://open.substack.com/pub/thedreydossier/p/the-true-cost-of-trump-accounts?r=5162w2&utm_medium=ios) (or watch the video) explaining what’s going on with these accounts, and exposing the hidden costs that come with this reward - like surrendering your baby’s biometric data
The $1,000 federal seed for kids born 2025 through 2028 sits unclaimed until a parent files at trumpaccounts.gov or via IRS Form 4547, and 2025 babies are still covered retroactively. Free money with no income limit and no required contribution is rare, but default inaction forfeits it.
Latigo prices $345.6 million IPO at $18 a share
Latigo priced its IPO at $18 a share for $345.6 million, one of the largest biotech raises of the year and enough capital to push its non-opioid painkiller against Vertex's head start. Goldman Sachs, Jefferies, Leerink and Guggenheim ran the books.
Source: SEC filingEarnings split the session at the close: Airbnb's raised revenue outlook lifted it 15.1% while Trade Desk lost nearly a quarter of its value. Travel, optics and AI names carried the session; ad tech and crypto miners absorbed the damage.
Priced at $16 for a $150M Nasdaq debut
BlossomHill Therapeutics priced its IPO at $16 a share, raising $150 million with J.P. Morgan and Leerink leading the book. A deal that size for a precision oncology developer is a real test of how far the reopened biotech window extends.
Source: SEC filingSponsored
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
Priced at $8, raising $15 million on Nasdaq
Ticketplus priced its Nasdaq debut at $8 a share, a $15 million raise on just 1.875 million shares. That tiny float is the whole story: live-event ticketing exposure arrives in a micro-cap that can move hard on day one, with Roth Capital Partners leading the deal alongside Bancroft Capital and MDB Capital.
Source: SEC filing
